Effects of Short-term Growth Hormone in HIV-infected Patients

This study has been completed.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
First received: November 20, 2008
Last updated: December 6, 2013
Last verified: October 2013
Results First Received: October 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone
Drug: Growth Hormone Releasing Hormone

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
GH 6mcg/kg/d Recombinant human growth hormone 6mcg/kg SC once daily
GH 2mg Daily Recombinant human growth hormone 2mg SC once daily
Growth Hormone Releasing Hormone Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
Total Total of all reporting groups

Baseline Measures
    GH 6mcg/kg/d     GH 2mg Daily     Growth Hormone Releasing Hormone     Total  
Number of Participants  
[units: participants]
  8     12     5     25  
[units: participants]
<=18 years     0     0     0     0  
Between 18 and 65 years     8     12     5     25  
>=65 years     0     0     0     0  
[units: years]
Mean (Standard Deviation)
  49  (7)     49  (6)     47  (4)     48  (6)  
[units: participants]
Female     0     2     0     2  
Male     8     10     5     23  
Region of Enrollment  
[units: participants]
United States     8     12     5     25  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug   [ Time Frame: after 2 weeks treatment ]

2.  Secondary:   Insulin Sensitivity   [ Time Frame: after two weeks treatment ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was completed early due to the lack of availability of study drug for one of the arms.

  More Information